Video

Marine Compound Discovery Shows Promise of Improved Drug Treatment for COPD Patients

University of Florida pharmacy researchers have isolated a compound from blue-green algae that may inhibit the progression of pulmonary disease.

University of Florida pharmacy researchers have isolated a compound from blue-green algae that may inhibit the progression of pulmonary disease.

Related Videos
Related Content
Varicella zoster or chickenpox virus, ai illustration. A herpes virus which cause chickenpox and shingles - Image credit: Cristina | stock.adobe.com
December 20th 2024

Study: Fatal Disseminated Herpes Zoster in Immunocompetent Individuals

Kennedy Ferruggia, Assistant Editor
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

Mounjaro tirzepatide GLP-1 receptor agonist vial | Image Credit: © Cynthia - stock.adobe.com
December 20th 2024

FDA Affirms Decision on Tirzepatide Shortage Resolved, Sets Transition Period for Compounding

Alexandra Gerlach, Associate Editor
Public Health Matters: Pharmacists as Frontline Health Providers: Collaborating for Better Patient Outcomes
November 21st 2024

Public Health Matters: Pharmacists as Frontline Health Providers: Collaborating for Better Patient Outcomes

Christina M. Madison, PharmD, FCCP, AAHIVP
Postpartum depression -- Image credit: grooveriderz | stock.adobe.com
December 20th 2024

Study: Predictive Screening Models Less Likely to Widen Existing Health Disparities in PMAD Diagnosis

Gillian McGovern, Assistant Editor
FDA Approval, Familial Chyomicronemia Syndrome | Image Credit: Tyler Olson | stock.adobe.com
December 20th 2024

FDA Approves Olezarsen as Adjunct to Diet for Familial Chylomicronemia Syndrome

Ashley Gallagher, Associate Editor